Lipoprotein(a) 20 items
What CETP inhibitors do to Lp(a), and where that fits. See also the sister site lp-a.org.
Studies
- BROOKLYN: obicetrapib cuts LDL-C by 36.3% and Lp(a) by 45.9% in 354 patients with heterozygous familial hypercholesterolaemia (Nat Med 2026)
- Obicetrapib lowers Lp(a) by 37% in a 2,356-patient pooled analysis, with similar absolute reduction across baseline strata (Eur Heart J 2026)
- Obicetrapib review: an amphipathic CETP inhibitor cutting LDL-C 30-51%, apoB 20-33% and Lp(a) 30-57% across BROOKLYN, BROADWAY and TANDEM (Cardiol Rev 2025)
- Updated meta-analysis of 3,381 patients: obicetrapib cuts LDL-C by 37% and, unexpectedly, new-onset diabetes by 12% (Am J Prev Cardiol 2025)
- Anacetrapib lowers lipoprotein(a) by cutting its production rate 41%, not by speeding its clearance (ATVB 2017)
- Evacetrapib cuts small LDL particles by up to 95% and lipoprotein(a) by up to 40%, alone or added to statins (J Clin Lipidol 2016)
- Meta-analysis of 3,088 patients: obicetrapib cuts LDL-C by 32% and Lp(a) by 36% with no excess adverse events (Vasc Dis 2026)
- Meta-analysis of nine RCTs in 3,516 patients confirms obicetrapib lowers LDL-C by 37% and Lp(a) by 41% with no excess adverse events (Cardiol Rev 2025)
- CETP inhibitors cut lipoprotein(a) by 46 percent, the largest reduction among all lipid-lowering drug classes in a 147-trial meta-analysis (Atherosclerosis 2025)
- Meta-analysis of nine RCTs in 3,706 patients: obicetrapib plus ezetimibe adds a further 17.8% LDL-C reduction over obicetrapib alone (J Clin Lipidol 2025)
- In ACCELERATE, elevated Lp(a) only predicted death, MI and stroke when hsCRP was also 2 mg/L or higher (JAMA Cardiol 2020)
- Anacetrapib, the new CETP inhibitor: raises large HDL2 and pre-beta HDL, lowers Lp(a) via ApoA production, and shows a hint of glucose benefit (Diseases 2017)
- Growth hormone replacement transiently lowers CETP concentration and LDL cholesterol together, revealing a shared regulatory link (Lipids 2001)
- Review surveys how current and emerging lipid therapies, including CETP inhibitors, affect lipoprotein(a) levels (Eur Cardiol 2026)
- Meta-analysis of five early RCTs in 288 patients: obicetrapib reduces LDL-C by 41% and raises HDL-C by 157% (J Clin Lipidol 2025)
- Lp(a) review names obicetrapib the only drug besides apheresis to meaningfully lower Lp(a), cutting it by 40% (Nutr Metab Cardiovasc Dis 2025)
- GWAS confirms CETP as one of only three genome-wide loci for Lp(a) levels while discovering a novel APOH locus (Arterioscler Thromb Vasc Biol 2020)
- In dal-Outcomes, Lp(a) after acute coronary syndrome did not predict recurrent ischaemic events on background statin therapy (JAMA Cardiol 2018)
- Adding torcetrapib to atorvastatin lowers lipoprotein(a) by 11 percent while modestly raising PCSK9, an ILLUMINATE biomarker substudy finds (J Clin Lipidol 2018)
- CETP inhibitors lower lipoprotein(a) by around 50 percent, review notes, in comparison with apheresis and other new drugs (Atheroscler Suppl 2017)